StrokeVASSTIINCT01996137
VASSTII: An Exploratory Clinical Study on a VASST IITreadmill System for Post Stroke Gait Rehabilitation.
A study testing VASST II treadmill in people with Stroke and Hemiplegic Gait, run by Tan Tock Seng Hospital at 1 site in Singapore.
Trial summary
An exploratory clinical study on a Variable Speed and Sensing Treadmill system(VASST) for hemiparetic gait rehabilitation after stroke. Building upon the positive results of VASST I conducted in 2012, VASST II will be an open label pilot trial of 11 subjects screened for eligibility by TTSH medical and rehabilitation… Read more about this study
- Who is it for?
- Ages 21 to 80 years
- Conditions the study is for
- Stroke, Hemiplegic Gait
- What is being tested?
- VASST II treadmill
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 11 participants
- Where
- 1 siteSingapore
- Study dates
- 24 Sep 2018to 15 Jun 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- First ever stroke (ischaemic or haemorrhagic) confirmed on CT or MR imaging
- Aged 21 - 80 years
- Stroke duration of > 3 months - 24 months (subacute -chronic stroke)
- Able to walk overground at a self-selected speed of >0.2m/s with or without walking aids or lower limb orthoses for at least 150 meters with at most minimal aid or supervision.
- Functional ambulation category (FAC >/= 2) (subject needs at most minimal assistance to walk)
Who cannot join
- Cardiovascular conditions such as uncontrolled hypertension/hypotension, angina pectoris, recent myocardial infarction, congestive cardiac failure, known echocardiographic ejection fraction < 40%, chronic arrhythmias (e.g. atrial fibrillation), pacemaker, uncontrolled Diabetes Mellitus.; within 3 months of study screening
- Terminal illness such as advanced malignancy, end stage renal failure, neurodegenerative diseases with life expectancy of < 6 months.
- Aphasia (inability to obey 2 step commands), cognitive impairment, untreated depression or psychiatric disorder.
- Severe hearing or visual impairment despite aids.
- Active lower limb arthritis, lower limb or joint pain (Visual Analogue Scale) >5/10, fixed orthopaedic deformities and peripheral vascular disease of the lower limb which could be worsened by treadmill training.
- Moderate to severe lower limb spasticity or spasms (Modified Ashworth Scale >2)
Show all 9Show fewer
- Active trunk skin conditions, known abdominal aortic aneurysm, anticoagulation with warfarin precluding safe fit of unweighting gait harness.
- Body weight > 130kg.
- Pregnancy.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Exploratory Clinical Study on a Variable Speed and Sensing Treadmill (VASST II) System for Hemiparetic Gait Rehabilitation After Stroke
An exploratory clinical study on a Variable Speed and Sensing Treadmill system(VASST) for hemiparetic gait rehabilitation after stroke.
Building upon the positive results of VASST I conducted in 2012, VASST II will be an open label pilot trial of 11 subjects screened for eligibility by TTSH medical and rehabilitation team Study hypotheses : Training on VASST may result in a gain of +40% - 50% for distance walked and +10-20% of gait speed compared to baseline and response rate of 85% and serious adverse event rate of <10%.
Read the detailed description
A recent collaboration with Ngee Ann Polytechnic's team from the Biomedical Engineering Centre, Electronic \& Computer Engineering Division, School Of Engineering Singapore yielded the VASST I; an innovative product, the result of co development between NP and TTSH rehabilitation centre's CART (Centre for Advanced Rehabilitation Therapeutics) was supported by a competitive grant. (EMBC paper ref, SIRF)
VASST I incorporates the following features which enhance manual treadmill training:
- Sensing mechanisms to track user's self-activated actions during exercise.
- Automated speed-control to adapt to a user's gait speed and pattern.
- Safety sensing to slow down the treadmill when the user is unable to sustain the treadmill speed in order to avert a potential fall.
- Overhead safety harness without body weight support for reduction of fall risk.
- Software tools to collect vital clinical data regarding ambulatory gait speed, distance and time walked during treatment.
A recently completed proof of concept trial in June 2013 yielded encouraging results in 10 chronic poststroke hemiplegic subjects. All subjects completed the trial without any adverse events. The clinical team was able to smoothly test-bed VASST in 10 subjects with good subjective feedback. Following 12 hour - long supervised training sessions over 4 weeks, there were significant gains from baseline for measures of gait quantity (+30.1%) and gait speed (+8.7%). These gains were maintained for up to 4 weeks after training ceased. The response rate was 80% and positive feedback was obtained in 80% of subjects. Objective measurements were obtained using independent kinematic gait analysis using the Gaitrite system.
With these encouraging results, the combined TTSH and Ngee Ann medical and bioengineering teams have brought the co-development to a deeper level, leading to VASST II which is conceptualized as a pre-commercialisation prototype.
Additional technological improvements include:
- Automated unweighting subsystem of up to 20% body weight support to benefit more severely impaired subjects in terms of reduction of physical fatigue during ambulation and to reduce destabilization or fall risk during higher gait training speeds.
- Hand grip sensors to intelligently guide progression of training speeds
- Instrumentation subsystem including sensors to record spatial and temporal gait measurements during gait training such as step and stride length, gait speed / distance walked. An anticipated sensor accuracy of +/- 1.27 cm similar to the Gaitrite system in measuring step length may potentially allow ambulatory gait monitoring, obviating the need for additional independent post-training analysis using a gait measurement instrument such as Gaitrite.
- Real-time feedback subsystem with graphical LCD display which is interactive and varied in order reduce boredom and motivate users.
- Wireless data transfer subsystem for data storage and analysis to a laptop computer for the treating therapist.
Research objectives
- To provide clinical inputs into VASST II via systematic hazard analyses, in order to arrive at a prototype which may attract commercial interest for licensing and manufacture and eventual deployment to ambulatory rehabilitation clinics in hospitals and day rehabilitation centres.
- To conduct of a pilot clinical trial using VASST II for 11 subacute to chronic (>3 months) hemiplegic stroke patients in an ambulatory setting.
- To obtain pre and post outcomes using standardized clinical scales and objective measurements of gait parameters during exercise. (gait speed, quantity, cadence, step length)
- To obtain subjective feedback with regards to their experience after using VASST II from research subjects and therapists.
- Conditions
- Stroke, Hemiplegic Gait
- Being tested
- VASST II treadmill
- Keywords
- Stroke, Treadmill, Gait Speed
- Medical subject headings
- Stroke, Gait Disorders, Neurologic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VASST II treadmillDevice
Also called Variable Automated Speed and Sensing Treadmill version II
Supervised treadmill training under physiotherapist
| Study group | Role | What they receive |
|---|---|---|
| VASST II | Experimental | Stroke patients selected to undergo VASST II treadmill training for 60 minutes x15 sessions over 5 weeks Outcomes at week 0.3 6.12.24 Receives: Device: VASST II treadmill |
What is being measured
The primary outcome is the main question the study is designed to answer.
6 minute walk test
distance (metres) walked in 6 minutes
Measured: 6 weeks
Secondary outcomes (2)
Gait speed
seconds taken to walk 10 metre
Measured: 6 weeks
Functional ambulation category FAC
Walking independence description
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Nov 2013 (estimated)
- Study start24 Sep 2018
- Primary completion15 Jun 2019
- Study completion15 Jun 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- 1 hour of VASST II training, total 15 sessions over 5 weeks continuously
- Masking
- None (open label)
- Enrolment
- 11 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tan Tock Seng Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Ngee Ann Polytechnic Singapore
- Responsible party
- Principal investigator, Chua Sui Geok, Karen, Tan Tock Seng Hospital
- Investigators
- Karen SG Chua, MBBS,FRCP, Principal investigator, Tan Tock Seng Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01996137
- Sponsor's protocol ID
- NHGDSRB_D_2013/01042
- Acronym
- VASSTII
- Status last verified
- Sep 2019
- First submitted
- 21 Nov 2013
- Last updated
- 13 Sep 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Sep 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Exploratory Clinical Study on a Variable Speed and Sensing Treadmill (VASST II) System for Hemiparetic Gait Rehabilitation After Stroke
- ClinicalTrials.gov ID
- NCT01996137
- Acronym / sponsor ID
- VASSTII / NHGDSRB_D_2013/01042
- Conditions
- Stroke, Hemiplegic Gait
- Keywords
- Stroke, Treadmill, Gait Speed
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 11 participants (actual)
- Lead sponsor
- Tan Tock Seng HospitalUniversity, hospital or other
- Collaborators
- Ngee Ann Polytechnic Singapore
- Study start
- 24 Sep 2018 (actual)
- Primary completion
- 15 Jun 2019 (actual)
- Study completion
- 15 Jun 2019 (actual)
- First posted
- 27 Nov 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An exploratory clinical study on a Variable Speed and Sensing Treadmill system(VASST) for hemiparetic gait rehabilitation after stroke.
Building upon the positive results of VASST I conducted in 2012, VASST II will be an open label pilot trial of 11 subjects screened for eligibility by TTSH medical and rehabilitation team Study hypotheses : Training on VASST may result in a gain of +40% - 50% for distance walked and +10-20% of gait speed compared to baseline and response rate of 85% and serious adverse event rate of <10%.
Detailed description
A recent collaboration with Ngee Ann Polytechnic's team from the Biomedical Engineering Centre, Electronic \& Computer Engineering Division, School Of Engineering Singapore yielded the VASST I; an innovative product, the result of co development between NP and TTSH rehabilitation centre's CART (Centre for Advanced Rehabilitation Therapeutics) was supported by a competitive grant. (EMBC paper ref, SIRF)
VASST I incorporates the following features which enhance manual treadmill training:
- Sensing mechanisms to track user's self-activated actions during exercise.
- Automated speed-control to adapt to a user's gait speed and pattern.
- Safety sensing to slow down the treadmill when the user is unable to sustain the treadmill speed in order to avert a potential fall.
- Overhead safety harness without body weight support for reduction of fall risk.
- Software tools to collect vital clinical data regarding ambulatory gait speed, distance and time walked during treatment.
A recently completed proof of concept trial in June 2013 yielded encouraging results in 10 chronic poststroke hemiplegic subjects. All subjects completed the trial without any adverse events. The clinical team was able to smoothly test-bed VASST in 10 subjects with good subjective feedback. Following 12 hour - long supervised training sessions over 4 weeks, there were significant gains from baseline for measures of gait quantity (+30.1%) and gait speed (+8.7%). These gains were maintained for up to 4 weeks after training ceased. The response rate was 80% and positive feedback was obtained in 80% of subjects. Objective measurements were obtained using independent kinematic gait analysis using the Gaitrite system.
With these encouraging results, the combined TTSH and Ngee Ann medical and bioengineering teams have brought the co-development to a deeper level, leading to VASST II which is conceptualized as a pre-commercialisation prototype.
Additional technological improvements include:
- Automated unweighting subsystem of up to 20% body weight support to benefit more severely impaired subjects in terms of reduction of physical fatigue during ambulation and to reduce destabilization or fall risk during higher gait training speeds.
- Hand grip sensors to intelligently guide progression of training speeds
- Instrumentation subsystem including sensors to record spatial and temporal gait measurements during gait training such as step and stride length, gait speed / distance walked. An anticipated sensor accuracy of +/- 1.27 cm similar to the Gaitrite system in measuring step length may potentially allow ambulatory gait monitoring, obviating the need for additional independent post-training analysis using a gait measurement instrument such as Gaitrite.
- Real-time feedback subsystem with graphical LCD display which is interactive and varied in order reduce boredom and motivate users.
- Wireless data transfer subsystem for data storage and analysis to a laptop computer for the treating therapist.
Research objectives
- To provide clinical inputs into VASST II via systematic hazard analyses, in order to arrive at a prototype which may attract commercial interest for licensing and manufacture and eventual deployment to ambulatory rehabilitation clinics in hospitals and day rehabilitation centres.
- To conduct of a pilot clinical trial using VASST II for 11 subacute to chronic (>3 months) hemiplegic stroke patients in an ambulatory setting.
- To obtain pre and post outcomes using standardized clinical scales and objective measurements of gait parameters during exercise. (gait speed, quantity, cadence, step length)
- To obtain subjective feedback with regards to their experience after using VASST II from research subjects and therapists.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- 1 hour of VASST II training, total 15 sessions over 5 weeks continuously
| Arm | Type | Receives |
|---|---|---|
| VASST II | Experimental | Device: VASST II treadmillStroke patients selected to undergo VASST II treadmill training for 60 minutes x15 sessions over 5 weeks Outcomes at week 0.3 6.12.24 |
Who may qualify
- Ages
- 21 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- First ever stroke (ischaemic or haemorrhagic) confirmed on CT or MR imaging
- Aged 21 - 80 years
- Stroke duration of > 3 months - 24 months (subacute -chronic stroke)
- Able to walk overground at a self-selected speed of >0.2m/s with or without walking aids or lower limb orthoses for at least 150 meters with at most minimal aid or supervision.
- Functional ambulation category (FAC >/= 2) (subject needs at most minimal assistance to walk)
Key exclusion criteria (9 listed)
- Cardiovascular conditions such as uncontrolled hypertension/hypotension, angina pectoris, recent myocardial infarction, congestive cardiac failure, known echocardiographic ejection fraction < 40%, chronic arrhythmias (e.g. atrial fibrillation), pacemaker, uncontrolled Diabetes Mellitus.; within 3 months of study screening
- Terminal illness such as advanced malignancy, end stage renal failure, neurodegenerative diseases with life expectancy of < 6 months.
- Aphasia (inability to obey 2 step commands), cognitive impairment, untreated depression or psychiatric disorder.
- Severe hearing or visual impairment despite aids.
- Active lower limb arthritis, lower limb or joint pain (Visual Analogue Scale) >5/10, fixed orthopaedic deformities and peripheral vascular disease of the lower limb which could be worsened by treadmill training.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VASST II treadmillAlso: Variable Automated Speed and Sensing Treadmill version IISupervised treadmill training under physiotherapist | Device | VASST II |
Primary outcome
6 minute walk test
Time frame: 6 weeks
distance (metres) walked in 6 minutes
2 secondary outcomes
Gait speed
Time frame: 6 weeks
Functional ambulation category FAC
Time frame: 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Sep 2019.
- Individual participant dataSharing planned: No
Related trials for Stroke
Not yet recruiting
Closed-Loop SCS-BCI for Post-Stroke Hemiplegia
Stroke, Motor Dysfunction
Active, not recruiting
Transferring Speed of Processing Gains to Everyday Cognitive Tasks After Stroke
Stroke, Cognitive Dysfunction
Not yet recruitingObservational study
A Speaking-Valve-Based Decannulation Protocol for Tracheostomized Stroke Patients
Stroke Patients, Tracheostomy
RecruitingPhase 4
Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals
Cerebrovascular Disorders
Not yet recruiting
Effect of Early Tendon Vibrations on Upper Limb Motor Recovery After a Stroke
Acute Stroke, Upper Limb Motor Deficit
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Karen SG Chua, MBBS,FRCP principal investigator
Tan Tock Seng Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing VASST II treadmill in people with Stroke and Hemiplegic Gait, run by Tan Tock Seng Hospital at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
6 minute walk test (time frame: 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Sep 2019.